Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure

Executive Summary

Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.

You may also be interested in...



Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure

The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.

Heart Failure Pipeline Review: Amgen's Omecamtiv And Merck's Vericiguat Step Up To Plate

In addition to small molecules, stem cell therapies promise to help rejuvenate the chronic heart failure pipeline, but high prices and invasive procedures may limit their use to end-stage patients, and skepticism about efficacy persists.

Bayer/Merck Cardio Rx Collaboration Pumped Up By Consumer Deal

Merck sells consumer care business, but also buys into Bayer’s franchise of sGC modulators.

Topics

Related Companies

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel